R&D News | pharmaphorum

News

Asahi Kasei buys antiviral firm Aicuris for €780m

Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

Asahi Kasei buys antiviral firm Aicuris for €780m

Changes at the top of Sarepta, Alkermes, as CEOs depart

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

Astellas bets on Vir cancer drug, and other licensing deals

After CagriSema blow, Novo reveals data for obesity 'triple'

FDA delays verdict on AZ breast cancer drug

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks